|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00388622 |
|
Date of registration:
|
08/10/2006 |
|
Primary sponsor: |
|
|
Public title:
|
Improving Drug Use for Elderly Heart Failure Patients
|
|
Scientific title:
|
Improving Drug Use for Elderly Heart Failure Patients |
|
Date of first enrolment:
|
February 2001 |
|
Target sample size:
|
314 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00388622 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Michael D Murray, PharmD, MPH |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
UNC-Chapel Hill |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- age 50 and older
- prescription for at least one cardiovascular medication for heart failure
- plan to receive care and prescriptions at the study health care facility
- ability to hear within the normal range of conversation
- English speaking
- willingness to obtain echocardiography
Exclusion Criteria:
- dementia
Age minimum:
50 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Heart Failure
|
|
Intervention(s)
|
|
Behavioral: Pharmacist intervention
|
|
Primary Outcome(s)
|
|
Exacerbation of heart failure
|
|
Health-related quality of life
|
|
Medication adherence
|
|
Secondary Outcome(s)
|
|
Direct costs
|
|
Health care utilization
|
|
Patient satisfaction
|
|
Secondary ID(s)
|
|
R01-AG19105
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|